Literature DB >> 23919063

Genital tract infection of women in Southern Orissa with special reference to pelvic inflammatory disease.

Sarita Mohapatra1, Pritilata Panda, Banojini Parida.   

Abstract

Entities:  

Year:  2013        PMID: 23919063      PMCID: PMC3730485          DOI: 10.4103/0253-7184.112971

Source DB:  PubMed          Journal:  Indian J Sex Transm Dis AIDS        ISSN: 2589-0557


× No keyword cloud information.
Sir, Genital tract infection (GTI) includes vulvitis, vaginitis, and cervicitis, which subsequently ascends to the upper genital tract causing pelvic inflammatory disease (PID).[1] Important causative organisms include Chlamydia trachomatis and Neisseria gonorrhoeae, Mycoplasma hominis, Ureaplasma urealyticum, Gardnerella vaginalis, and Escherichia coli.[2] Ninety sexually active females (20-45 yr age group) with complaints of abnormal vaginal discharge, lower abdominal pain, dyspareunia, irregular vaginal bleeding were taken as cases and 30 females without such complaints were included as controls. Five endocervical swabs were collected from each patient and processed for direct microscopic examination and culture. Sample was examined for curdy discharge, pH, and amine test with 10% KOH. Swab in the tube containing normal saline was checked for motile trophozoites of Trichomonas vaginalis under the low power microscope. Gram staining was done and examined for presence of clue cell. Culture of each specimen was done for aerobic bacterial isolation, Mycoplasma spp., and budding yeast cell. Isolated Mycoplasma strains on pleuropneumonia-like organism (PPLO) agar were identified on the basis of typical colonial morphology and further confirmation was done by Diene's stain and Giemsa stain. Serum from 60 cases (clinically diagnosed as PID) was tested for C. trachomatis IgM enzyme-linked immunosorbent assay (ELISA) (NovaTec). Maximum number of cases (48/90) of GTI was between 20-30 yrs age group [Table 1]. Majority of cases were married (housewives) followed by laborers. Intrauterine devices (IUD) were the predominant contraceptive method practised by the study groups. Vaginal discharge was the single most common presentation in these patients (25%). However, most of the patients had pruritus, dysuria, low backache, and dyspareunia along with vaginal discharge. Trophozoites of T. vaginalis were identified in wet mount preparation in three (3.3%) cases out of total 90. Mycoplasma spp. found to be the most common pathogen (17.8%) on culture isolation, followed by Staphylococcus aureus (16.6%) in the cases [Table 2]. In control group, S. epidermidis was the most commonly isolated bacteria. Culture isolation of different Mycoplasma spp. in cases revealed U. urealyticum was the commonest isolate in 12 (13.2%), followed by M. hominis four (4.4%). However, U. urealyticum was isolated in two (6.6%) from the controls. Sixteen (26.6%) out of 60 PID cases were seropositive for C. trachomatis by IgM ELISA test. No seropositive result was obtained from the 20 controls. So, out of the total 60 PID cases, Mycoplasma spp. was found in 18.3% of cases and C. trachomatis was found in 26.6%, and both were found in 6.6%. Total 10 (11.1%) cases were found culture positive in Sabouraud dextrose agar (SDA) agar out of which Candida albicans is the predominant followed by C. tropicalis.
Table 1

Demographic profile of the study group

Table 2

Culture isolation of different microbes

Demographic profile of the study group Culture isolation of different microbes Microbial flora of the female genital tract presents as an extensive and diversified spectrum of pathogenic and non-pathogenic organisms. While gonorrhea and Chlamydia have long been associated with acute PID, bacterial vaginosis caused by different pathogens has emerged as another risk factor for upper genital tract infection.[34] In this study, the association of selected microbes in the causation of lower GTI (vaginitis/cervicitis) and upper genital tract infection (PID) has been studied. Use of (IUD) traditionally believed to confer an elevated risk of PID due to bacterial contamination at the time of insertion.[5] In the present study, more than 49% of total patients used intrauterine devices as contraceptive measures. Mycoplasma spp. has been suggested as a cause of wide range of diseases of the female genital tract.[4] The association of Mycoplasma spp. with GTI cases was found to be significant (P < 0.05) in our study. Although, 3.3% incidence of T. vaginalis was observed by microscopy in this study, other diagnostic modalities like culture and molecular methods could not be carried out for technical reasons. Despite limitations, the multifactorial etiology is well-established in patients with PID. In our study, both Mycoplasma spp. and C. trachomatis were found in patients with PID. However, the antibiotics used for genital chlamydial infection are less effective against Mycoplasma spp. Diagnostic laboratories where the facility for culture of etiological agents such as Mycoplasma spp. and Chlamydia are unavailable, an empirical treatment for acute PID must include agents effective against these organisms.
  4 in total

Review 1.  Pelvic inflammatory disease: new diagnostic criteria and treatment.

Authors:  Richard H Beigi; Harold C Wiesenfeld
Journal:  Obstet Gynecol Clin North Am       Date:  2003-12       Impact factor: 2.844

Review 2.  Sexually transmitted diseases. Pelvic inflammatory disease and infertility in women.

Authors:  R L Sweet
Journal:  Infect Dis Clin North Am       Date:  1987-03       Impact factor: 5.982

3.  Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Chinese women with genital infectious diseases.

Authors:  Changtai Zhu; Jinming Liu; Yang Ling; Chunlei Dong; Tingting Wu; Xiaoyuan Yu; Yanfeng Hou; Liping Dong; Xiaowei Cheng
Journal:  Indian J Dermatol Venereol Leprol       Date:  2012 May-Jun       Impact factor: 2.545

4.  Lower genital tract infections in HIV-seropositive women in India.

Authors:  Vandana Goel; P Bhalla; Abha Sharma; Y M Mala
Journal:  Indian J Sex Transm Dis AIDS       Date:  2011-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.